ECSP23041779A - Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1Info
- Publication number
- ECSP23041779A ECSP23041779A ECSENADI202341779A ECDI202341779A ECSP23041779A EC SP23041779 A ECSP23041779 A EC SP23041779A EC SENADI202341779 A ECSENADI202341779 A EC SENADI202341779A EC DI202341779 A ECDI202341779 A EC DI202341779A EC SP23041779 A ECSP23041779 A EC SP23041779A
- Authority
- EC
- Ecuador
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
- 229940126027 positive allosteric modulator Drugs 0.000 title abstract 2
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de acuerdo con la fórmula (I), el cual es un modulador alostérico positivo de D1 y de acuerdo con esto, de beneficio como agente farmacéutico para el tratamiento de enfermedades en las cuales los receptores de D1 desempeñan un papel.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20215255 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23041779A true ECSP23041779A (es) | 2023-07-31 |
Family
ID=73855651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202341779A ECSP23041779A (es) | 2020-12-18 | 2023-06-06 | Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20240059665A1 (es) |
| EP (1) | EP4263517B1 (es) |
| JP (1) | JP7798891B2 (es) |
| KR (1) | KR20230121849A (es) |
| CN (1) | CN116583280A (es) |
| AU (1) | AU2021403603A1 (es) |
| CA (1) | CA3202993A1 (es) |
| CL (1) | CL2023001609A1 (es) |
| CO (1) | CO2023008864A2 (es) |
| DK (1) | DK4263517T3 (es) |
| EC (1) | ECSP23041779A (es) |
| ES (1) | ES2999070T3 (es) |
| FI (1) | FI4263517T3 (es) |
| HR (1) | HRP20241657T1 (es) |
| HU (1) | HUE069739T2 (es) |
| IL (1) | IL303693A (es) |
| LT (1) | LT4263517T (es) |
| MX (1) | MX2023007155A (es) |
| PE (1) | PE20240632A1 (es) |
| PL (1) | PL4263517T3 (es) |
| PT (1) | PT4263517T (es) |
| RS (1) | RS66356B1 (es) |
| SI (1) | SI4263517T1 (es) |
| UA (1) | UA130559C2 (es) |
| WO (1) | WO2022129268A1 (es) |
| ZA (1) | ZA202305336B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026022198A1 (en) * | 2024-07-25 | 2026-01-29 | UCB Biopharma SRL | Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| BR112017007123B1 (pt) * | 2014-10-08 | 2023-01-31 | Ucb Biopharma Sprl | Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica |
| WO2017178377A1 (en) | 2016-04-13 | 2017-10-19 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| MY210361A (en) | 2019-07-01 | 2025-09-13 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
-
2021
- 2021-12-16 CA CA3202993A patent/CA3202993A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086066 patent/WO2022129268A1/en not_active Ceased
- 2021-12-16 IL IL303693A patent/IL303693A/en unknown
- 2021-12-16 ES ES21836545T patent/ES2999070T3/es active Active
- 2021-12-16 US US18/267,331 patent/US20240059665A1/en active Pending
- 2021-12-16 PL PL21836545.0T patent/PL4263517T3/pl unknown
- 2021-12-16 LT LTEPPCT/EP2021/086066T patent/LT4263517T/lt unknown
- 2021-12-16 HU HUE21836545A patent/HUE069739T2/hu unknown
- 2021-12-16 AU AU2021403603A patent/AU2021403603A1/en active Pending
- 2021-12-16 HR HRP20241657TT patent/HRP20241657T1/hr unknown
- 2021-12-16 DK DK21836545.0T patent/DK4263517T3/da active
- 2021-12-16 JP JP2023536408A patent/JP7798891B2/ja active Active
- 2021-12-16 FI FIEP21836545.0T patent/FI4263517T3/fi active
- 2021-12-16 PT PT218365450T patent/PT4263517T/pt unknown
- 2021-12-16 PE PE2023001839A patent/PE20240632A1/es unknown
- 2021-12-16 RS RS20241393A patent/RS66356B1/sr unknown
- 2021-12-16 KR KR1020237024170A patent/KR20230121849A/ko active Pending
- 2021-12-16 SI SI202130244T patent/SI4263517T1/sl unknown
- 2021-12-16 UA UAA202303402A patent/UA130559C2/uk unknown
- 2021-12-16 CN CN202180085033.9A patent/CN116583280A/zh active Pending
- 2021-12-16 EP EP21836545.0A patent/EP4263517B1/en active Active
- 2021-12-16 MX MX2023007155A patent/MX2023007155A/es unknown
-
2023
- 2023-05-16 ZA ZA2023/05336A patent/ZA202305336B/en unknown
- 2023-06-05 CL CL2023001609A patent/CL2023001609A1/es unknown
- 2023-06-06 EC ECSENADI202341779A patent/ECSP23041779A/es unknown
- 2023-07-04 CO CONC2023/0008864A patent/CO2023008864A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202305336B (en) | 2024-09-25 |
| PL4263517T3 (pl) | 2025-03-31 |
| EP4263517B1 (en) | 2024-10-02 |
| EP4263517A1 (en) | 2023-10-25 |
| US20240059665A1 (en) | 2024-02-22 |
| JP2023553671A (ja) | 2023-12-25 |
| CN116583280A (zh) | 2023-08-11 |
| LT4263517T (lt) | 2025-01-10 |
| SI4263517T1 (sl) | 2025-01-31 |
| ES2999070T3 (en) | 2025-02-24 |
| RS66356B1 (sr) | 2025-01-31 |
| AU2021403603A9 (en) | 2024-09-26 |
| HRP20241657T1 (hr) | 2025-02-14 |
| CA3202993A1 (en) | 2022-06-23 |
| FI4263517T3 (fi) | 2024-12-09 |
| CO2023008864A2 (es) | 2023-08-18 |
| WO2022129268A1 (en) | 2022-06-23 |
| PT4263517T (pt) | 2024-12-17 |
| AU2021403603A1 (en) | 2023-07-13 |
| JP7798891B2 (ja) | 2026-01-14 |
| UA130559C2 (uk) | 2026-03-18 |
| HUE069739T2 (hu) | 2025-04-28 |
| CL2023001609A1 (es) | 2023-12-22 |
| KR20230121849A (ko) | 2023-08-21 |
| MX2023007155A (es) | 2023-06-28 |
| IL303693A (en) | 2023-08-01 |
| DK4263517T3 (da) | 2024-12-09 |
| PE20240632A1 (es) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015493A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| UY38768A (es) | Inhibidores de bckdk | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
| PE20151890A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| MX2024007938A (es) | Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| CL2019003486A1 (es) | Compuestos que contienen nitrogeno sustituido. | |
| MX2024007929A (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| ECSP23041779A (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1 | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| BR112022007543A2 (pt) | Derivados de tiofeno como inibidores de xantina oxidase e aplicação dos mesmos | |
| UY38072A (es) | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |